Chromosome-positive acute lymphocytic leukemia

Hematology/Oncology Clinics of North America

Volumn 15, Issue 1, 2001, Pages 21-36

  Radich, J P ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; PREDNISONE; PROTEIN P190; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ACUTE LYMPHOCYTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CELL LINEAGE; GENE TRANSLOCATION; HUMAN; MINIMAL RESIDUAL DISEASE; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; ADULT; ALLOTRANSPLANTATION; ANIMAL; CANCER TRANSPLANTATION; CELL TRANSFORMATION; CHILD; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EXPERIMENTAL LEUKEMIA; GENETICS; MORTALITY; MOUSE; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; TRANSGENIC MOUSE;

ADULT; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; CHILD; DISEASE-FREE SURVIVAL; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASM, RESIDUAL; PHILADELPHIA CHROMOSOME; PHOSPHORYLATION; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0035093711     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70198-2     Document Type: Article

References (77)

1. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
2. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: Chronic myelogenous leukemia presenting in lymphoid blast vs Ph + acute lymphoblastic leukemia
3. Adult Philadelphia-chromosome-positive acute lymphoblastic leukemia: Experience of treatments during a ten-year period
4. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
5. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
6. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
7. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia
8. Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia
9. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia
10. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL
11. A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia
12. A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias
13. First intron and M-bcr breakpoints are restricted to the lymphoid lineage in Philadelphia positive acute lymphoblastic leukemia
14. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study
15. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique
16. bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia
17. Clinical efficacy and safety, of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
18. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
19. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
20. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: Determination by analysis of individual colonies with the polymerase chain reaction
21. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
22. Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia
23. Potential molecules implicated in down-stream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase
24. New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level
25. The bcr gene in Philadelphia chromosome positive acute lymphoblastic leukemia
26. Acute leukaemia in bcr/abl transgenic mice
27. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia
28. Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia
29. A novel 203 kD aberrant BCR-ABL product in a girl with Philadelphia chromosome positive acute lymphoblastic leukaemia
30. Significance of the p210 versus p190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia
31. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro
32. Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia
33. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity
34. Kinetic selectivity of complementary nucleic acids: Bcr-abl-directed antisense RNA and ribozymes
35. Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia
36. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811
37. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport
38. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia
39. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
40. Molecular diagnosis of the Philadelphia chromosome in chronic myelogenous and acute lymphoblastic leukemias by PCR
41. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells
42. PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR-ABL-positive acute lymphoblastic leukaemia
43. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: Possible eradication of minimal residual disease by marrow transplantation
44. A minute chromosome in human chronic granulocytic leukemias
45. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: Abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth
46. A novel acute lymphoid leukaemia type BCR/ABL transcript in chronic myelogenous leukaemia
47. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow
48. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: Characteristics, treatment results, and prognosis in 41 patients
49. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway
50. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation
51. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction
52. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: Durable responses to chemotherapy associated with low initial white blood cell counts
53. Heterogeneity of genomic fusion of BCR and ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia
54. Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis
55. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia
56. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92
57. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome
58. Prognostic implications of breakpoint and lineage heterogeneity in Philadelphia-positive acute lymphoblastic leukemia: A review
59. Philadelphia positive acute lymphoblastic leukemia in adults: Age distribution, BCR breakpoint and prognostic significance
60. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party
61. Variable Philadelphia breakpoints and potential lineage restriction of bcr rearrangement in acute lymphoblastic leukemia
62. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
63. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide
64. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides
65. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission
66. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene
67. Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia
68. Detection and significance of bcr-abl mRNA transcripts and fusion proteins in Philadelphia-positive adult acute lymphoblastic leukemia
69. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: A report from the Children's Cancer Group
70. Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy
71. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism
72. Pathophysiology of CML: Do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone?
73. BCR/ABL p210 and p190 cause distinct leukemia in transgenic mice
74. Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice
75. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study (8762)
76. Prospective karyotype analysis in adult acute lymphoblastic leukemia: The Cancer and Leukemia Group B experience
77. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation